- Algernon Pharmaceuticals (AGN) has appointed Dr. Jacky Smith to its Scientific Advisory Board
- Dr. Smith is a Professor of Respiratory Medicine and an expert in the mechanisms behind coughing and the testing of anti-cough therapies
- She is also a Professor at the University of Manchester and an Honorary Consultant at the Manchester University NHS Foundation Trust
- Shares in Algernon Pharmaceuticals have remained at 8 cents, with a market cap of C$5.74 million
Algernon Pharmaceuticals (AGN), has announced the appointment of Dr. Jacky Smith to its Scientific Advisory Board.
A Professor of Respiratory Medicine, Dr. Smith is a leading expert in understanding the mechanisms behind coughing in respiratory diseases and the testing of new anti-cough therapies.
Dr. Smith is the Director of the NIHR Manchester Clinical Research Facility and leads the Rapid Translational Incubator Theme of the Manchester Biomedical Research Centre.
She is also a Professor at the University of Manchester and an Honorary Consultant at Manchester University NHS Foundation Trust.
“I am very pleased to join the Algernon Medical and Scientific advisory board,” said Dr. Smith.
“I had investigated a similar mechanism to Algernon’s NP-120 (Ifenprodil) compound a number of years ago and we definitely saw a signal in that study. I am hopeful the NP-120 Phase 2 study will be a success which could pave the way for new treatment options for both IPF and chronic cough patients in the future.”
Earlier this year, Algernon Pharmaceuticals appointed Sydney-based Novotech as the contract research organization for its Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the NP-120 drug.
The study is expected to begin in the second quarter of 2020.
Shares in Algernon Pharmaceuticals have remained steady at 8 cents, with a market cap of C$5.74 million.